Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patientsSophie A. Kurk, Anne M. May, Lieke H. J. Simkens et al.|Journal of Cachexia Sarcopenia and Muscle|2019Cited by 107
Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patientsSophie A. Kurk, Anne M. May, Rebecca K. Stellato et al.|American Journal of Clinical Nutrition|2019Cited by 22
Impact of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) on time to progression and overall survival (OS) in metastatic colorectal cancer (mCRC) patients.Sophie A. Kurk, Anne M. May, Petra H.M. Peeters et al.|Journal of Clinical Oncology|2017Cited by 6
Impact of sarcopenia on dose limiting toxicities in metastatic colorectal cancer patients (mCRC pts) receiving palliative systemic treatmentSophie A. Kurk, Anne M. May, Petra H.M. Peeters et al.|Annals of Oncology|2017Cited by 4
Trajectory of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) predicts time to progression (TTP) in metastatic colorectal cancer (mCRC) patientsSophie A. Kurk, Anne M. May, Marion Jourdan et al.|Annals of Oncology|2018Cited by 0